Targeting the beta‐catenin/APC pathway: a novel mechanism to explain the cyclooxygenase‐2‐independent anticarcinogenic effects of celecoxib in human colon carcinoma cells

Abstract
Celecoxib, a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug, is a new anticarcinogenic agent. Its antitumor effects depend on the one hand on its COX-2-inhibiting potency, but...
Funding Information
  • Deutsche Forschungsgemeinschaft (GR2011/1‐1, GRK 757/1)